SCHEMBL5162193

SCHEMBL5162193

CCNc1nc(SCCCc2ccccc2)nc2c1nc(Br)n2-c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TMIGD3 P0DMS9 5/20 0.42
ADORA2A P29274 5/20 0.42
ADORA2B P29275 5/20 0.42
ADORA1 P30542 5/20 0.42
ALPL P05186 1/20 0.36
KDM1A O60341 1/20 0.36
ESR1 P03372 1/20 0.36
ESR2 Q92731 1/20 0.36
CYP1A2 P05177 2/20 0.36
CYP2C9 P11712 2/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
CASP1 P29466 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5161412 0.95 ADORA2A (0.41) TMIGD3ADORA2AADORA2BADORA1KDM1A
SCHEMBL5161088 0.92 ALDH1A1 (0.42) TMIGD3ADORA2AADORA2BADORA1CYP1A2
SCHEMBL5159207 0.86 ALDH1A1 (0.44) TMIGD3ADORA2AADORA2BADORA1CYP1A2
SCHEMBL5163808 0.82 ADORA1 (0.47) TMIGD3ADORA2AADORA2BADORA1MEN1
SCHEMBL5162993 0.81 TMIGD3 (0.54) TMIGD3ADORA2AADORA2BADORA1CYP1A2
SCHEMBL5163187 0.80 TMIGD3 (0.45) TMIGD3ADORA2AADORA2BADORA1ESR1
SCHEMBL5160526 0.79 ADORA2A (0.53) TMIGD3ADORA2AADORA2BADORA1CYP1A2
SCHEMBL5158701 0.77 ADORA2B (0.42) TMIGD3ADORA2AADORA2BADORA1CYP1A2
SCHEMBL5162148 0.74 ADORA2A (0.48) TMIGD3ADORA2AADORA2BADORA1CYP1A2
SCHEMBL5163828 0.72 ADORA2A (0.47) TMIGD3ADORA2AADORA2BADORA1KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7189730-B2 A2A adenosine receptor antagonists CV THERAPEUTICS, INC. (US) 2007-03-13 US disclosed
EP-1456209-B1 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS INC (US) 2007-02-28 EP disclosed
US-20030149060-A1 A2A adenosine receptor antagonists CV THERAPEUTICS, INC. 2003-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149060-A1 A2A adenosine receptor antagonists ADORA2A, ADORA2B, ADORA3 TMIGD3 1730/4885ADORA2A 1/4885ADORA2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.